R-006
Risperidone solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
About This Item
Productos recomendados
grado
certified reference material
formulario
liquid
Características
Snap-N-Spike®/Snap-N-Shoot®
envase
ampule of 1 mL
fabricante / nombre comercial
Cerilliant®
concentración
1.0 mg/mL in methanol
técnicas
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
aplicaciones
clinical testing
formato
single component solution
temp. de almacenamiento
−20°C
cadena SMILES
CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1
InChI
1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
Clave InChI
RAPZEAPATHNIPO-UHFFFAOYSA-N
Información sobre el gen
human ... DRD2(1813) , HTR2A(3356) , HTR2C(3358)
Descripción general
Aplicación
- Vascular Syndromes and Neuroleptic Therapy: RisperiDonesolution has been investigated for its role in inducing severe vascular occlusion-like syndromes in rat models. Research highlights its potential implications for understanding drug-induced vascular problems and testing therapies like BPC 157, a gastric pentadecapeptide with promising therapeutic effects (Strbe et al., 2023).
- UHPLC Method Development: RisperiDoneis a focal point in the development of an advanced UHPLC method using the "Method Operable Design Region" (MODR) approach. This method is designed for the assay and purity determination of risperiDonein various formulations, crucial for maintaining stringent quality controls in pharmaceutical manufacturing (Pawar et al., 2022).
- Optimizing Antipsychotic Dose Regimens: Research incorporates risperiDoneto explore Maximum A Posteriori (MAP) Bayesian modelling, merging drug plasma concentrations and dopamine receptor occupancy. This approach aims to customize antipsychotic dosing to enhance therapeutic outcomes in individual patients, emphasizing personalized medicine in psychiatry (Ismail et al., 2022).
- Antioxidant-mediated Drug Degradation: Studies on risperiDonealso cover the formulation aspects, such as its inclusion in poly(ethylene carbonate) systems to control drug degradation through antioxidant mediation. This research is pivotal in developing sustained-release formulations that enhance drug stability and efficacy (Bohr et al., 2020).
- Patient-reported Outcomes in Schizophrenia Treatment: RisperiDonesolution is studied for its effectiveness in treating schizophrenia, particularly assessing patient-reported outcomes in long-term therapy settings. This research helps gauge patient satisfaction and treatment efficacy, which is essential for optimizing mental health therapies (Dhanda et al., 2019).
Información legal
Producto relacionado
Palabra de señalización
Danger
Frases de peligro
Consejos de prudencia
Clasificaciones de peligro
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
Órganos de actuación
Eyes,Central nervous system
Código de clase de almacenamiento
3 - Flammable liquids
Clase de riesgo para el agua (WGK)
WGK 2
Punto de inflamabilidad (°F)
49.5 °F - closed cup
Punto de inflamabilidad (°C)
9.7 °C - closed cup
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Los clientes también vieron
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico